Keybank National Association OH Sells 478 Shares of Omnicell, Inc. (OMCL)
Keybank National Association OH trimmed its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 8.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,466 shares of the company’s stock after selling 478 shares during the period. Keybank National Association OH’s holdings in Omnicell were worth $236,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in OMCL. BlackRock Inc. lifted its stake in shares of Omnicell by 139,475.2% in the first quarter. BlackRock Inc. now owns 4,487,343 shares of the company’s stock valued at $182,412,000 after buying an additional 4,484,128 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of Omnicell by 99.6% in the first quarter. Wells Fargo & Company MN now owns 561,295 shares of the company’s stock valued at $22,817,000 after buying an additional 280,017 shares in the last quarter. Tributary Capital Management LLC bought a new position in shares of Omnicell in the first quarter valued at $8,908,000. Westfield Capital Management Co. LP lifted its stake in shares of Omnicell by 29.7% in the first quarter. Westfield Capital Management Co. LP now owns 925,244 shares of the company’s stock valued at $37,611,000 after buying an additional 211,698 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Omnicell by 324.4% in the first quarter. Russell Investments Group Ltd. now owns 204,440 shares of the company’s stock valued at $8,311,000 after buying an additional 156,264 shares in the last quarter. 96.35% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Keybank National Association OH Sells 478 Shares of Omnicell, Inc. (OMCL)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/16/keybank-national-association-oh-sells-478-shares-of-omnicell-inc-omcl.html.
Omnicell, Inc. (OMCL) opened at 49.10 on Friday. The company’s 50 day moving average is $50.08 and its 200-day moving average is $43.42. The company’s market capitalization is $1.84 billion. Omnicell, Inc. has a 52-week low of $30.35 and a 52-week high of $52.70.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.02. The company had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. Omnicell’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.38 EPS. Equities analysts anticipate that Omnicell, Inc. will post $1.30 EPS for the current fiscal year.
A number of research analysts have weighed in on the stock. Benchmark Co. raised their price objective on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. BidaskClub lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $40.00 price objective on shares of Omnicell in a research note on Sunday, July 30th. Dougherty & Co raised their price objective on shares of Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Finally, Craig Hallum raised their price target on shares of Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $51.57.
In related news, EVP Robin Gene Seim sold 9,780 shares of the company’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $48.97, for a total value of $478,926.60. Following the transaction, the executive vice president now owns 55,896 shares in the company, valued at approximately $2,737,227.12. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Randall A. Lipps sold 31,527 shares of the company’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $42.87, for a total transaction of $1,351,562.49. Following the completion of the transaction, the chairman now owns 196,551 shares in the company, valued at approximately $8,426,141.37. The disclosure for this sale can be found here. In the last quarter, insiders sold 212,089 shares of company stock worth $10,266,363. 3.77% of the stock is currently owned by company insiders.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.